MDMarcel Dihné

Marcel Dihné

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcel Dihné has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Encephalopathic Susac’s Syndrome associated with livedo racemosa in a young woman before the completion of family planning

    by Maik Engeholm, Beate Leo-Kottler, Hansjörg Rempp, Tobias Lindig, Holger Lerche, Ilka Kleffner, Melanie Henes, Marcel Dihné

    Susac’s Syndrome (SS) consists of the triad of encephalopathy, branch retinal artery occlusions (BRAO) and hearing loss (HL). Histopathologically, SS is characterised by a microangiopathy, and some observations suggest that an immune-mediated damage of endothelial cells might play a role. These findings also implicate a similarity between SS and other autoimmune diseases, most notably juvenile dermatomyositis (JDM). However, SS and JDM are commonly thought to affect distinct and non-overlapping sets of organs, and it is currently not clear how these specificities arise. Moreover, in the absence of clinical trials, some authors suggest that therapeutic approaches in SS should rely on the model of other autoimmune diseases such as JDM.


  • Open Access

    Episodic itch in a case of spinal glioma

    by Stefan Wolking, Holger Lerche, Marcel Dihné

    Itch is a frequent complaint reported by patients and is usually ascribed to dermatological or metabolic causes. In neurological disorders, however, it is a very unusual symptom and thus its neurological aetiology is likely to be overlooked. There are only very few reports about permanent itch related to lesions of the central nervous system. To our knowledge we report the first case of episodic itch associated with a central nervous lesion.


  • Open Access

    In vitro neuronal network activity in NMDA receptor encephalitis

    by Sabine U Jantzen, Stefano Ferrea, Claudia Wach, Kim Quasthoff, Sebastian Illes, Dag Scherfeld, Hans-Peter Hartung, Rüdiger J Seitz, Marcel Dihné

    Anti-NMDA-encephalitis is caused by antibodies against the N-methyl-D-aspartate receptor (NMDAR) and characterized by a severe encephalopathy with psychosis, epileptic seizures and autonomic disturbances. It predominantly occurs in young women and is associated in 59% with an ovarian teratoma.


  • Neues aus der Epileptologie

    by M. Dihné, T. Schmidt-Wilcke, N. Kurt Focke, Y. Weber, H. Lerche

    In den letzten Jahren wurden von der Internationalen Liga gegen Epilepsie die Definition einer pharmakoresistenten Epilepsie sowie eine revidierte Terminologie und neue Konzepte zur Einteilung epileptischer Anfälle und Epilepsien vorgestellt. Derzeit viel diskutiert wird das Konzept der sog. rationalen Polytherapie, nachdem Medikamente mit unterschiedlichem Nebenwirkungsspektrum und verschiedenen Wirkmechanismen besser zu kombinieren seien als solche mit ähnlichen oder gleichen Mechanismen. In diesem Zusammenhang ist die Einführung neuer antikonvulsiv wirkender Medikamente zu begrüßen, von denen die zugelassenen Substanzen Lacosamid (Blockade von Natriumkanälen durch selektive Verstärkung der langsamen Inaktivierung) und Retigabin (als erster Kaliumkanalaktivator) sowie das wahrscheinlich bald verfügbare Perampanel (als erster selektiver AMPA-Rezeptor-Antagonist) neue Wirkprinzipien aufweisen. Weiterhin wurde die Tiefenhirnstimulation im anterioren Thalamus als neue, nichtmedikamentöse Therapiemöglichkeit zugelassen. Hinsichtlich der genetischen Untersuchungen bei Epilepsien sind neue, pathophysiologisch interessante Gene beschrieben worden. Die Sequenziertechniken der neuen Generation sind sowohl für die Wissenschaft als auch bereits für die Diagnostik von großem Nutzen. Bei einigen Epilepsien ist die Kenntnis der genetischen Befunde auch im Alltag wichtig, da Zusatzdiagnostik vermieden und spezifische Therapien zeitnah begonnen werden können. Im Bereich der Bildgebung gibt es neue computerunterstützte Nachbearbeitungsmethoden, die besonders bei bislang MRT-negativen Patienten eine unmittelbare Bedeutung haben können. Ein vielversprechendes Potenzial haben zudem kombinierte Techniken wie EEG-fMRT oder auch Konnektivitätsanalysen, beide bedürfen jedoch noch weiterer Validierung. In the last years, the International League against Epilepsy has introduced the definition of a pharmacoresistant epilepsy and a proposal for a revised terminology and concepts to classify epileptic seizures and epilepsies. Under current discussion is the concept of the so-called “rational polytherapy” according to which drugs with different mechanisms of action and distinct side effects should rather be combined instead of drugs with similar or identical mechanisms. In this context, the recent introduction of new antiepileptic drugs which exhibit novel mechanisms of action is welcome, such as lacosamide (blockage of sodium channels by selective enhancement of slow inactivation) and retigabine (the first potassium channel enhancer), and perampanel (the first selective AMPA-receptor antagonist) which will be hopefully available soon. Also deep brain stimulation within the anterior thalamic nucleus has been approved as an alternative non-pharmacological treatment. In the genetic field, novel genes were described pointing to new pathophysiological pathways. The development of next generation sequencing techniques significantly improves both research and diagnostic genetic investigations. In special types of epilepsy, the underlying genetic defect helps to avoid additional diagnostic steps and may support the early start of specific therapies. Novel concepts of neuroimaging, in particular computer-assisted post-processing, may improve the diagnostic work-up for previously MRI-negative patients. Combined imaging methods like EEG-fMRI or connectivity analyses have shown potential but will need further evaluation.